See more : Amasten Fastighets AB (publ) (AMAST.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anhui Anke Biotechnology (Group) Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Vista Outdoor Inc. (VSTO) Income Statement Analysis – Financial Results
- Exel Composites Oyj (EXL1V.HE) Income Statement Analysis – Financial Results
- Ji-Haw Industrial Co.,Ltd. (3011.TW) Income Statement Analysis – Financial Results
- Ningbo Water Meter (Group) Co., LTD. (603700.SS) Income Statement Analysis – Financial Results
- China Oil HBP Science & Technology Co., Ltd (002554.SZ) Income Statement Analysis – Financial Results
Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ)
About Anhui Anke Biotechnology (Group) Co., Ltd.
Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It also provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care and anti-aging products; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits, as well as paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. The company was founded in 2000 and is based in Hefei, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.87B | 2.33B | 2.17B | 1.70B | 1.71B | 1.46B | 1.10B | 849.22M | 635.76M | 542.41M | 430.35M | 337.94M | 267.92M | 227.93M | 190.64M | 156.49M | 125.87M | 127.77M |
| Cost of Revenue | 664.62M | 503.37M | 432.42M | 361.08M | 376.21M | 291.17M | 244.24M | 219.21M | 181.22M | 157.29M | 117.06M | 91.99M | 78.61M | 64.60M | 53.01M | 45.53M | 37.58M | 45.51M |
| Gross Profit | 2.20B | 1.83B | 1.74B | 1.34B | 1.34B | 1.17B | 852.03M | 630.01M | 454.53M | 385.12M | 313.29M | 245.95M | 189.30M | 163.33M | 137.63M | 110.96M | 88.29M | 82.26M |
| Gross Profit Ratio | 76.81% | 78.41% | 80.06% | 78.78% | 78.03% | 80.08% | 77.72% | 74.19% | 71.50% | 71.00% | 72.80% | 72.78% | 70.66% | 71.66% | 72.19% | 70.91% | 70.14% | 64.38% |
| Research & Development | 254.68M | 166.01M | 166.54M | 128.76M | 120.09M | 87.32M | 70.17M | 51.78M | 35.87M | 29.41M | 25.70M | 23.45M | 22.42M | 9.98M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 67.29M | 33.26M | 29.31M | 27.27M | 24.10M | 23.38M | 19.38M | 22.46M | 14.57M | 11.85M | 7.68M | 8.20M | 9.35M | 8.25M | 25.05M | 18.87M | 15.89M | 19.84M |
| Selling & Marketing | 472.39M | 734.35M | 812.44M | 679.54M | 701.27M | 640.62M | 371.29M | 268.17M | 218.50M | 190.30M | 155.39M | 120.66M | 88.61M | 78.09M | 63.31M | 49.59M | 41.36M | 39.96M |
| SG&A | 1.02B | 767.61M | 841.75M | 706.80M | 725.37M | 664.00M | 390.67M | 290.63M | 233.07M | 202.16M | 163.07M | 128.85M | 97.96M | 86.34M | 88.36M | 68.46M | 57.25M | 59.80M |
| Other Expenses | -5.81M | 81.97M | 98.64M | 53.98M | 83.45M | -1.03M | 191.54K | 12.28M | 7.76M | 4.04M | 4.99M | 10.27M | 5.16M | 10.82M | 5.53M | 1.68M | 1.72M | 1.59M |
| Operating Expenses | 1.32B | 1.02B | 1.11B | 889.55M | 928.91M | 825.69M | 529.03M | 410.87M | 305.85M | 263.82M | 216.01M | 175.45M | 143.60M | 113.67M | 90.65M | 70.19M | 58.59M | 60.88M |
| Cost & Expenses | 1.94B | 1.52B | 1.54B | 1.25B | 1.31B | 1.12B | 773.27M | 630.08M | 487.07M | 421.11M | 333.07M | 267.45M | 222.21M | 178.27M | 143.66M | 115.71M | 96.17M | 106.39M |
| Interest Income | 5.89M | 4.81M | 5.42M | 13.60M | 9.79M | 692.26K | 418.41K | 882.16K | 2.41M | 5.90M | 5.13M | 5.47M | 11.38M | 2.28M | 413.37K | -0.07 | -0.56 | -0.57 |
| Interest Expense | 2.94M | 1.52M | 1.62M | 1.62M | 3.66M | 3.30M | 2.12M | 2.89M | 96.98K | 238.33K | 55.09K | 29.84K | 206.73K | 550.75K | 1.42M | 3.68M | 4.40M | 3.54M |
| Depreciation & Amortization | 101.11M | 88.88M | 88.75M | 70.29M | 66.52M | 59.02M | 55.91M | 48.29M | 26.96M | 23.31M | 16.07M | 13.49M | 14.97M | 12.09M | 8.73M | 8.89M | 9.08M | 10.08M |
| EBITDA | 1.02B | 921.94M | 403.49M | 483.19M | 249.43M | 366.12M | 392.88M | 283.62M | 184.59M | 151.26M | 122.01M | 99.57M | 88.89M | 73.57M | 61.40M | 49.67M | 38.78M | 31.46M |
| EBITDA Ratio | 35.69% | 40.01% | 34.17% | 30.56% | 27.10% | 27.28% | 35.49% | 33.30% | 29.36% | 28.49% | 28.60% | 29.70% | 33.75% | 32.92% | 32.39% | 31.81% | 30.64% | 26.46% |
| Operating Income | 923.98M | 841.99M | 660.06M | 424.04M | 401.78M | 310.63M | 329.05M | 219.31M | 150.14M | 122.67M | 101.05M | 75.64M | 69.26M | 50.27M | 45.75M | 40.46M | 26.25M | 15.59M |
| Operating Income Ratio | 32.24% | 36.12% | 30.44% | 24.92% | 23.46% | 21.25% | 30.02% | 25.82% | 23.62% | 22.62% | 23.48% | 22.38% | 25.85% | 22.06% | 24.00% | 25.85% | 20.85% | 12.20% |
| Total Other Income/Expenses | -4.05M | -8.15M | -2.32M | -7.90M | -1.74M | -1.03M | 191.54K | 12.22M | 5.83M | 4.04M | 4.83M | 10.25M | 28.93M | 10.64M | 5.50M | 1.68M | 1.70M | 1.59M |
| Income Before Tax | 919.93M | 833.85M | 295.12M | 416.14M | 163.41M | 309.60M | 329.24M | 231.23M | 155.97M | 126.71M | 105.88M | 85.89M | 73.72M | 60.91M | 51.25M | 42.14M | 27.95M | 17.18M |
| Income Before Tax Ratio | 32.10% | 35.77% | 13.61% | 24.46% | 9.54% | 21.18% | 30.03% | 27.23% | 24.53% | 23.36% | 24.60% | 25.42% | 27.52% | 26.72% | 26.88% | 26.93% | 22.20% | 13.45% |
| Income Tax Expense | 61.34M | 96.13M | 91.73M | 69.60M | 53.02M | 44.84M | 47.46M | 33.36M | 23.54M | 17.94M | 16.01M | 11.94M | 11.34M | 9.27M | 6.68M | 6.07M | 6.45M | 2.34M |
| Net Income | 847.23M | 703.26M | 206.63M | 358.96M | 124.47M | 263.17M | 277.74M | 197.30M | 136.25M | 109.85M | 89.87M | 73.95M | 63.32M | 51.98M | 44.57M | 34.55M | 22.71M | 15.73M |
| Net Income Ratio | 29.56% | 30.17% | 9.53% | 21.10% | 7.27% | 18.01% | 25.34% | 23.23% | 21.43% | 20.25% | 20.88% | 21.88% | 23.64% | 22.81% | 23.38% | 22.08% | 18.04% | 12.31% |
| EPS | 0.52 | 0.43 | 0.13 | 0.22 | 0.08 | 0.17 | 0.18 | 0.13 | 0.10 | 0.08 | 0.06 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.02 | 0.02 |
| EPS Diluted | 0.52 | 0.43 | 0.13 | 0.22 | 0.08 | 0.17 | 0.18 | 0.13 | 0.10 | 0.08 | 0.06 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.02 | 0.02 |
| Weighted Avg Shares Out | 1.63B | 1.64B | 1.64B | 1.64B | 1.64B | 1.56B | 1.55B | 1.51B | 1.40B | 1.40B | 1.39B | 1.36B | 1.35B | 1.08B | 1.11B | 976.72M | 963.08M | 974.62M |
| Weighted Avg Shares Out (Dil) | 1.63B | 1.64B | 1.64B | 1.64B | 1.64B | 1.58B | 1.55B | 1.53B | 1.43B | 1.40B | 1.39B | 1.37B | 1.35B | 1.08B | 1.11B | 976.72M | 963.08M | 974.62M |
Source: https://incomestatements.info
Category: Stock Reports